Endocrine tumors as part of inherited tumor syndromes

Advances in Anatomic Pathology

Volumn 18, Issue 3, 2011, Pages 206-218

  Zhang, Yaxia ^a   Nosé, Vĝnia ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

endocrine tumors; familial diseases; inherited tumor syndrome; multiple endocrine neoplasia

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CALCIUM; CORTICOTROPIN; GROWTH HORMONE; PARATHYROID HORMONE; PROTEIN RET;

ADENOMATOUS POLYP; ADRENAL CORTEX; ADRENAL CORTEX TUMOR; ADRENAL MEDULLA; AUTONOMIC NERVOUS SYSTEM; AUTOSOMAL DOMINANT DISORDER; BECKWITH WIEDEMANN SYNDROME; CARNEY COMPLEX; COWDEN SYNDROME; ENDOCRINE DISEASE; ENDOCRINE TUMOR; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILIAL CANCER; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; FAMILIAL ISOLATED HYPERPARATHYROIDISM; FAMILIAL ISOLATED PITUITARY ADENOMA; GENE MUTATION; GONADOTROPH ADENOMA; GROWTH HORMONE SECRETING ADENOMA; HEREDITARY HYPERPARATHYROIDISM JAW TUMOR; HUMAN; HYPOPHYSIS ADENOMA; MOLECULAR GENETICS; MULTIPLE ENDOCRINE ADENOMATOSIS; NEONATAL SEVERE HYPERPARATHYROIDISM; NEUROFIBROMATOSIS; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; PARATHYROID TUMOR; PATHOGENESIS; PATHOLOGIST; PENDRED SYNDROME; PHEOCHROMOCYTOMA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; SIPPLE SYNDROME; THYROID CANCER; THYROID GLAND; THYROID MEDULLARY CARCINOMA; VON HIPPEL LINDAU DISEASE; WERNER SYNDROME;

ADENOMA; ADRENAL GLAND NEOPLASMS; CARNEY COMPLEX; ENDOCRINE GLAND NEOPLASMS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; MULTIPLE ENDOCRINE NEOPLASIA; PANCREATIC NEOPLASMS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PITUITARY NEOPLASMS; THYROID NEOPLASMS;

EID: 79955091316     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182169916     Document Type: Review

References (83)

1. Erdheim J. Normal and pathological histology of thyroid, parathyroid and pituitary.. Beit Z Path Anat Z Allg Path. 1903;33:158-236.
2. Carney JA. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol. 2005;29:254-274. (Pubitemid 40170645)
3. Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23:543-554.
4. Burlacu MC, Tichomirowa M, Daly A, et al. Familial pituitary adenomas. Presse Med. 2009;38:112-116.
5. Daly AF, Tichomirowa MA, Beckers A. Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. Horm Res. 2009;71 (suppl 1):105-111.
6. Daly AF, Beckers A. Update on the treatment of pituitary adenomas: familial and genetic considerations. Acta Clin Belg. 2008;63:418-424.
7. Verloes A, Stevenaert A, Teh BT, et al. Familial acromegaly: case report and review of the literature. Pituitary. 1999;1:273-277.
8. Dreijerink KM, Varier RA, van Beekum O, et al. The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. Mol Cell Biol. 2009;29:5060-5069.
9. Dreijerink KM, Lips CJ, Timmers HT. Multiple endocrine neoplasia type 1: a chromatin writeŕs block. J Intern Med. 2009;266:53-59.
10. Dreijerink KM, Hoppener JW, Timmers HM, et al. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat Clin Pract Endocrinol Metab. 2006;2:562-570. (Pubitemid 44536604)
11. Gracanin A, Dreijerink KM, van der Luijt RB, et al. Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis. Cancer Res. 2009;69:6371-6374.
12. Falchetti A, Marini F, Luzi E, et al. Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med. 2009;11:825-835.
13. Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87:457-465. (Pubitemid 34158204)
14. Capella C, Riva C, Leutner M, et al. Pituitary lesions in multiple endocrine neoplasia syndrome (MENS) type 1. Pathol Res Pract. 1995;191:345-347.
15. Raverot G, Arnous W, Calender A, et al. Familial pituitary adenomas with a heterogeneous functional pattern: clinical and genetic features. J Endocrinol Invest. 2007;30:787-790. (Pubitemid 350238207)
16. Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32:534-543. (Pubitemid 351458295)
17. ÓBrien T, ÓRiordan DS, Gharib H, et al. Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery. 1996;39:273-278.
18. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86:4041-4046. (Pubitemid 32848510)
19. Bertherat J. Carney complex (CNC). Orphanet J Rare Dis. 2006;1:21.
20. Horvath A, Bossis I, Giatzakis C, et al. Large deletions of the PRKAR1A gene in Carney complex. Clin Cancer Res. 2008;14: 388-395. (Pubitemid 351226105)
21. Kirschner LS, Sandrini F, Monbo J, et al. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum Mol Genet. 2000;9: 3037-3046. (Pubitemid 32000777)
22. Stratakis CA, Carney JA, Lin JP, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome: analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest. 1996;97:699-705. (Pubitemid 26057088)
23. Chahal HS, Chapple JP, Frohman LA, et al. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21:419-427.
24. Tahir A, Chahal HS, Korbonits M. Molecular genetics of the aip gene in familial pituitary tumorigenesis. Prog Brain Res. 2010;182:229-253.
25. Tichomirowa MA, Daly AF, Beckers A. Familial pituitary adenomas. J Intern Med. 2009;266:5-18.
26. Carling T. Molecular pathology of parathyroid tumors. Trends Endocrinol Metab. 2001;12:53-58. (Pubitemid 33714189)
27. Waldmann J, Lopez CL, Langer P, et al. Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. Br J Surg. 2010;10:1528-1534.
28. Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis. 2006;1:45.
29. Santoro M, Melillo RM, Carlomagno F, et al. Molecular biology of the MEN2 gene. J Intern Med. 1998;243:505-508. (Pubitemid 28312248)
30. Lakhani VT, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med. 2007;58:253-265. (Pubitemid 46706513)
31. Bhadada SK, Rao DS. Hyperparathyroidism-jaw tumor syndrome. Endocr Pract. 2009;15:276-277.
32. Iacobone M, Masi G, Barzon L, et al. Hyperparathyroidismjaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg. 2009;394:817-825.
33. Stalberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg. 2009;33:2234-2243.
34. Guarnieri V, Scillitani A, Muscarella LA, et al. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab. 2006;91:2827-2832. (Pubitemid 44271719)
35. Hannan FM, Nesbit MA, Christie PT, et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab. 2008;4:53-58. (Pubitemid 350291116)
36. Mizusawa N, Uchino S, Iwata T, et al. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf). 2006;65:9-16.
37. Iacobone M, Barzon L, Porzionato A, et al. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery. 2007;142:984-991. (Pubitemid 350184117)
38. Pollak MR, Chou YH, Marx SJ, et al. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism: effects of mutant gene dosage on phenotype. J Clin Invest. 1994;93:1108-1112.
39. Al Shanafey S, Al Hosaini R, Al Ashwal A, et al. Surgical management of severe neonatal hyperparathyroidism: one centeŕs experience. J Pediatr Surg. 2010;45:714-717.
40. Hendy GN, Guarnieri V, Canaff L. Chapter 3 Calcium-Sensing Receptor and Associated Diseases. Prog Mol Biol Transl Sci. 2009;89C:31-95.
41. Hendy GN, D́Souza-Li L, Yang B, et al. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat. 2000;16:281-296.
42. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
43. Richards ML. Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid. 2010;20: 707-713.
44. Alsanea O, Clark OH. Familial thyroid cancer. Curr Opin Oncol. 2001;13:44-51. (Pubitemid 32060043)
45. Alsanea O. Familial nonmedullary thyroid cancer. Curr Treat Options Oncol. 2000;1:345-351.
46. Dotto J, Nosé V. Familial thyroid carcinoma: a diagnostic algorithm. Adv Anat Pathol. 2008;15:332-349.
47. Nosé V. Familial follicular cell tumors: classification and morphological characteristics. Endocr Pathol. 2010;21:207-211.
48. Nosé V. Thyroid cancer of follicular cell origin in inherited tumor syndromes. Adv Anat Pathol. 2010;17:428-436.
49. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet. 2008;16:1289-1300.
50. Harach HR, Soubeyran I, Brown A, et al. Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol. 1999;3:331-340.
51. Nosé V. Familial non-medullary thyroid carcinoma: an update. Endocr Pathol. 2008;19:226-240.
52. Zambrano E, Holm I, Glickman J, et al. Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated tumor syndromes. Endocr Pathol. 2004;15:55-64. (Pubitemid 38951809)
53. Harach HR, Lesueur F, Amati P, et al. Histology of familial thyroid tumours linked to a gene mapping to chromosome 19p13.2. J Pathol. 1999;189:387-393. (Pubitemid 29489224)
54. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22.
55. Groen EJ, Roos A, Muntinghe FL, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol. 2008;15:2439-2450.
56. Harb WJ, Sturgis EM. Differentiated thyroid cancer associated with intestinal polyposis syndromes: a review. Head Neck. 2009;31:1511-1519.
57. Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology. 1994;25:549-561.
58. Stratakis CA, Courcoutsakis NA, Abati A, et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab. 1997;82:2037-2043. (Pubitemid 27287558)
59. Kopp P, Pesce L, Solis-S JC. Pendred syndrome and iodide transport in the thyroid. Trends Endocrinol Metab. 2008;19: 260-268.
60. Dossena S, Rodighiero S, Vezzoli V, et al. Functional characterization of wild-type and mutated pendrin (SLC26A4), the anion transporter involved in Pendred syndrome. J Mol Endocrinol. 2009;43:93-103.
61. Ishikawa Y, Sugano H, Matsumoto T, et al. Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. Cancer. 1999;85:1345-1352. (Pubitemid 29125089)
62. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 2006;16: 181-186.
63. Bakhsh A, Kirov G, Gregory JW, et al. A new form of familial multi-nodular goitre with progression to differentiated thyroid cancer. Endocr Relat Cancer. 2006;13:475-483. (Pubitemid 43886670)
64. Uchino S, Noguchi S, Kawamoto H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002;26:897-902. (Pubitemid 36920283)
65. Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000;128:1043-1050.
66. McKay JD, Lesueur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 2001;69:440-446.
67. Malchoff CD, Sarfarazi M, Tendler B, et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab. 2000;85:1758-1764. (Pubitemid 32269272)
68. Bignell GR, Canzian F, Shayeghi M, et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet. 1997;61:1123-1130. (Pubitemid 27492321)
69. Pacini F, Castagna MG, Cipri C, et al. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22:475-485.
70. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565-612.
71. Stratakis CA. Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies. Horm Metab Res. 2007;39:467-473. (Pubitemid 46999856)
72. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer. 2007;14:13-28. (Pubitemid 47521719)
73. Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol. 2005;153:477-487. (Pubitemid 41568145)
74. Haase M, Willenberg HS. Adrenal cortical tumors and multiple endocrine neoplasia-related syndromes. Minerva Endocrinol. 2009;34:123-135.
75. Choufani S, Shuman C, Weksberg R. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet. 2010;154C: 343-354.
76. Karakas Z, Tugcu D, Unuvar A, et al. Li-Fraumeni syndrome in a Turkish family. Pediatr Hematol Oncol. 2010;27:297-305.
77. Dahia PL, Ross KN, Wright ME, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005;1:72-80.
78. van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10:764-771.
79. Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113:1807-1843.
80. Alexakis N, Connor S, Ghaneh P, et al. Hereditary pancreatic endocrine tumours. Pancreatology. 2004;4:417-433. (Pubitemid 39140441)
81. Ekeblad S. Islet cell tumours. Adv Exp Med Biol. 2010;654: 771-789.
82. Tisell LE, Ahlman H. Treatment of the pancreatic disease of multiple endocrine neoplasia type 1 (MEN 1). Acta Oncol. 1989;28:415-417.
83. Hough DM, Stephens DH, Johnson CD, et al. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol. 1994;162:1091-1094. (Pubitemid 24144976)